Fig. 2

Comparing reduction in parasite liver burden in two studies by mAb: Mice (N = 5) were dosed with AB311 or AB317 at 600, 300, 100 and 30 µg. Each study also had five naïve, infected mice (no mAb administered) and five mice receiving mAb1245 at 600 µg (control with no functional activity). Transgenic sporozoite challenge was administered at 16 h post administration of mAb. Points denote flux measured for each animal, and line represents the average from 5 individual mice per group. Groups containing naïve mice that do not receive any treatment and mice that receive a non-functional mAb (AB1245) are shown for both experiments